GlobeNewswire·Nov 12, 2026, 4:15 PM ET

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Prime Medicine, Inc. closed an underwritten public offering of 41,071,428 shares of common stock at $3.50 per share.
The offering included the full exercise of the underwriters' option to purchase 5,357,142 additional shares.
All shares were sold by Prime Medicine, generating approximately $143.7 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses.
Jefferies, TD Cowen, and Goldman Sachs & Co. LLC acted as joint book-running managers, while Oppenheimer & Co. and LifeSci Capital served as passive book-running managers.
The offering was conducted pursuant to a shelf registration statement on Form S-3ASR filed with the SEC on November 7, 2025, including amendments filed in March 2026.
Prime Medicine is advancing a portfolio of investigational gene editing therapies targeting liver, lung, immunology, and oncology diseases using its proprietary Prime Editing platform.
Investor and media contact information for Gregory Dearborn at Prime Medicine and Hannah Deresiewicz at Precision AQ was provided in the release.